Compare ECO & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECO | ADPT |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 2023 | 2019 |
| Metric | ECO | ADPT |
|---|---|---|
| Price | $55.45 | $14.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $42.00 | $17.78 |
| AVG Volume (30 Days) | 359.3K | ★ 1.4M |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | ★ 6.12% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,976,000.00 |
| Revenue This Year | $16.07 | $3.98 |
| Revenue Next Year | N/A | $22.72 |
| P/E Ratio | $18.60 | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $21.27 | $8.38 |
| 52 Week High | $57.29 | $20.76 |
| Indicator | ECO | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 64.52 | 54.83 |
| Support Level | $48.57 | $12.22 |
| Resistance Level | $57.29 | $15.38 |
| Average True Range (ATR) | 2.07 | 0.61 |
| MACD | 0.32 | 0.06 |
| Stochastic Oscillator | 83.98 | 76.94 |
Okeanis Eco Tankers Corp is an international owner and operator of a fleet of tanker vessels used for the transportation of crude oil. Its fleet consists of modern Suezmax and VLCC tankers that are designed in accordance with eco-efficiency standards, including features such as reduced fuel consumption, exhaust gas cleaning systems, and ballast water treatment systems. All of the company's revenue is derived from a single segment, the crude oil tanker segment. Geographically, the maximum revenue is generated from Europe, and the rest from Asia, North America, and South America.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.